ArticleNature communications2026
Discovery of 5' NAD capped viral RNAs reveals evolutionary divergent 5' metabolite capping across hepaciviruses.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
Abstract
Hepatitis C virus (HCV), an important pathogen and prototype hepacivirus, 5' caps its RNA with flavin adenine dinucleotide (FAD); no other 5' metabolite capped viral RNAs have been identified. Here, we establish NADzymeID, allowing specific identification of 5' nicotinamide adenine dinucleotide (NAD). Using NADzymeID, we find that Norway rat hepacivirus 1 (NrHV-1) and related hepaciviruses use 5' NAD capping, whereas the closest relatives of HCV use 5' FAD, thereby revealing evolutionary divergence of 5' capping. NrHV-1 replication is attenuated in absence of NAD, and NrHV-1 is cleared more rapidly in mice with reduced intrahepatic NAD levels. As observed for 5' FAD, 5' NAD protects viral RNA from RIG-I mediated innate immune sensing. Thus, despite evolutionary divergence, metabolite capping generally confers evasion of innate immune responses. These represent the first examples of 5' NAD capping for viruses, providing tools also to investigate the elusive function of cellular 5' metabolite caps.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.